EB-203

DRUG2 trials

Sponsors

EyebioKorea, Inc.

Conditions

HealthyNeovascular Age-related Macular Degeneration (nAMD)

Phase 1

Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers

CompletedNCT05538949

EyebioKorea, Inc.Healthy

Start: 2022-06-29End: 2022-10-07Updated: 2023-02-23

Phase 2

Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

RecruitingNCT06487039

EyebioKorea, Inc.Neovascular Age-related Macular Degeneration (nAMD)

Start: 2024-08-01End: 2026-01-31Target: 50Updated: 2024-08-27